Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Translation control of the immune checkpoint in cancer and its therapeutic targeting

(2019) Yichen Xu et al.   NATURE MEDICINE

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

(2019) Mauro Poggio et al.   CELL

Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells

(2019) Mu-Yang Huang et al.   FOOD AND CHEMICAL TOXICOLOGY

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

(2018) Chia-Wei Li et al.   CANCER CELL

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

(2018) Jong-Ho Cha et al.   MOLECULAR CELL

Palmitoylation stabilizes PD-L1 to promote breast tumor growth

(2018) Yi Yang et al.   CELL RESEARCH

HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity

(2018) Huanbin Wang et al.   Nature Chemical Biology

Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma

(2018) Michaël Cerezo et al.   NATURE MEDICINE

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

(2017) Vikram R. Juneja et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

(2017) V Atsaves et al.   LEUKEMIA

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

(2017) Shuguang Tan et al.   Nature Communications

Three Drugs Approved for Urothelial Carcinoma by FDA

(2017)   Cancer Discovery

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

(2017) Simon J. Hogg et al.   Cell Reports

Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy

(2017) Chunlin Li et al.   Cancer Immunology Research

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Immune Checkpoint Therapies in Prostate Cancer

(2016) Sangeeta Goswami et al.   CANCER JOURNAL

Abstract 4861: Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy

(2016) Pottayil Sasikumar et al.   CANCER RESEARCH

Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer

(2016) Brant A. Inman et al.   CLINICAL CANCER RESEARCH

From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway

(2016) Mei-Miao Zhan et al.   DRUG DISCOVERY TODAY

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

(2016) Krzysztof M. Zak et al.   Oncotarget

OncoBinder facilitates interpretation of proteomic interaction data by capturing coactivation pairs in cancer

(2016) Samya Van Coillie et al.   Oncotarget

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

(2016) Hengrui Zhu et al.   Cell Reports

Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy

(2015) Hao-Nan Chang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Nivolumab success in untreated metastatic melanoma

(2015) Emma Wilkinson   LANCET ONCOLOGY

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-mediated antitumor effect by type 2 diabetes drug, metformin

(2015) Shingo Eikawa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance

(2015) A M Martin et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Interaction of HIV-1 Nef Protein with the Host Protein Alix Promotes Lysosomal Targeting of CD4 Receptor

(2014) Nathaly A. Amorim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations

(2014) Geraldine O'Sullivan Coyne et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model

(2014) S. Chen et al.   Cancer Immunology Research

Antibody–drug conjugates: current status and future directions

(2013) Heidi L. Perez et al.   DRUG DISCOVERY TODAY

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Translational control of the activation of transcription factor NF-κB and production of type I interferon by phosphorylation of the translation factor eIF4E

(2012) Barbara Herdy et al.   NATURE IMMUNOLOGY

Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

(2012) N. Patsoukis et al.   Science Signaling

Cellular and molecular mechanisms of metformin: an overview

(2011) Benoit Viollet et al.   CLINICAL SCIENCE

COPII and the regulation of protein sorting in mammals

(2011) Giulia Zanetti et al.   NATURE CELL BIOLOGY

Identification and Structural Characterization of the ALIX-Binding Late Domains of Simian Immunodeficiency Virus SIVmac239 and SIVagmTan-1

(2010) Q. Zhai et al.   JOURNAL OF VIROLOGY

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression

(2010) L. Furic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy

(2009) H. Luo et al.   CARDIOVASCULAR RESEARCH

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

(2008) D. Y.-w. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

(2008) E. Lazar-Molnar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA